Skip to main content

Table 4 Number and proportion of patients reporting AEs during treatment, for events reported by at least 1% of patients in the FF or placebo arms

From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

Number of patients reporting event, n (%)

Placebo

nDPI

(n= 145)

Placebo

DISKUS

(n= 42)

FF

200 μg OD

(n= 140)

FF

100 μg

BD

(n= 142)

FP 200 μg OD

(n= 42)

FP 100 μg BD

(n= 43)

Any on-treatment AE

21 (14)

5 (12)

22 (16)

26 (18)

2 (5)

3 (7)

   URTI

2 (1)

0

7 (5)

7 (5)

0

0

   Sinusitis

0

1 (2)

1 (< 1)

2 (1)

0

0

   Pharyngitis

2 (1)

0

1 (< 1)

0

0

0

   Cellulitis

2 (1)

0

0

0

0

0

   Tooth infection

0

0

2 (1)

0

0

0

   Cough

0

0

0

2 (1)

0

0

   Headache

2 (1)

0

2 (1)

0

0

0

   Tension headache

0

0

2 (1)

0

0

0

  1. Data shown are for the ITT population.
  2. AE = adverse events; BD = twice daily; FF = fluticasone furoate; OD = once daily; URTI = upper respiratory tract infections.